article · Clinical Infectious Diseases

Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF–identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012–2017: A Retrospective Province-Wide Cohort Study

Andre Nyandwe Hamama Bulabula
Dieudonné Kalumuna
Karen R. Jacobson
Bertin C Bisimwa
Jacob Creswell
Robin M. Warren
Andreas H. Diacon
Rhoderick Machekano
Nadia A. Sam‐Agudu
Liliane Kitete
Jenna Nelson
Zacharie Kashongwe
Jean-Paul Chirambiza
Maunank Shah
Freddy Birembano
Grant Theron
Michel Kaswa
Eric Mulume Musafiri
Martin P. Grobusch
Patrick DMC Katoto
Jean B. Nachega

201825 citationsOpen accessUniversité de Kinshasa (UNIKIN)

Abstract

Favorable RR-TB cure rates are achievable in this post-conflict setting with a high RR-TB prevalence. An expanded Xpert scale-up; the prompt initiation of shorter, safer, highly effective MDR-TB regimens; and treatment adherence support are critically needed to optimize outcomes.

Research topics

Tuberculosis Research and Epidemiology
Diagnosis and treatment of tuberculosis
Mycobacterium research and diagnosis

Sustainable Development Goals

3Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1093/cid/ciy1105

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.